Mullol, J <br/><br/>
Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival.  [electronic resource] 

 -  Journal of biological regulators and homeostatic agents   
 - 403-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0393-974X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetates--pharmacology<br/>Adult<br/>Animals<br/>Cattle<br/>Cell Survival--drug effects<br/>Cyclopropanes<br/>Cytokines--biosynthesis<br/>Eosinophilia--drug therapy<br/>Eosinophils--drug effects<br/>Epithelial Cells--drug effects<br/>Female<br/>Granulocyte-Macrophage Colony-Stimulating Factor--biosynthesis<br/>Humans<br/>In Vitro Techniques<br/>Inflammation--drug therapy<br/>Interleukin-6--biosynthesis<br/>Interleukin-8--biosynthesis<br/>Leukotriene Antagonists--pharmacology<br/>Male<br/>Middle Aged<br/>Nasal Mucosa--drug effects<br/>Nasal Polyps--drug therapy<br/>Quinolines--pharmacology<br/>Rhinitis--drug therapy<br/>Sulfides